SCHEMBL6733409

SCHEMBL6733409

COCCOc1ccc(-c2cc(-c3cccc(N)c3)nc(-c3cccc(N)c3)c2)cc1OCCOC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 3/20 0.42
▸ NTRK1 P04629 1/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ PDPK1 O15530 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ EPHB4 P54760 1/20 0.40
▸ TEK Q02763 1/20 0.40
▸ FYN P06241 1/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ MAP4K4 O95819 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734212 0.80 MAPT (0.44) ALDH1A1MAPTHPGDNPC1RAB9A
SCHEMBL4061067 0.73 ALDH1A1 (0.55) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL29736247 0.73 ALDH1A1 (0.55) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL4764227 0.70 KDM1A (0.42) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL14389682 0.70 MEN1 (0.70) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL16316247 0.70 PDE4A (0.47) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL16871023 0.70 MEN1 (0.70) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL17525544 0.69 MAPT (0.50) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL980277 0.68 NTRK1 (0.58) KITNTRK1MEN1KMT2AKDM4E
SCHEMBL15684033 0.68 MEN1 (0.73) MEN1KMT2AKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis ARRHENIUS THOMAS (US) 2004-06-10 — — US disclosed
EP-1370250-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 — — EP disclosed
WO-2002076438-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis FLT1, FLT4, TEK KIT 57/4885NTRK1 338/4885MEN1 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback